TY - JOUR
T1 - Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms
AU - Matsunaga, Toshiyuki
AU - Yamane, Yumi
AU - Keiko, Lida
AU - Endo, Satoshi
AU - Banno, Yoshiko
AU - El-Kabbani, Ossama
AU - Hara, Akira
PY - 2011
Y1 - 2011
N2 - The human aldo-keto reductase (AKR) 1B10 is suggested as a tumor marker in various solid tumors. Using colon cancer cells, we found that AKR1B10 was induced with acquisition of resistance to the anticancer drug mitomycin-c (MMC). In the resistant cells, treatment with an AKR1B10 inhibitor decreased their MMC tolerance. In the nonresistant cells, overexpression and silencing of AKR1B10 decreased and increased, respectively, susceptibility to cytotoxic effects of MMC and 4-hydroxy-2-nonenal, which was formed as a product of lipid peroxidation by MMC treatment. These results suggest a role of AKR1B10 in the development of MMC resistance, which may be mediated by its ability to detoxify cytotoxic aldehydes including 4-hydroxy-2-nonenal. Anti-Cancer Drugs 22:402-408 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams Wilkins.
AB - The human aldo-keto reductase (AKR) 1B10 is suggested as a tumor marker in various solid tumors. Using colon cancer cells, we found that AKR1B10 was induced with acquisition of resistance to the anticancer drug mitomycin-c (MMC). In the resistant cells, treatment with an AKR1B10 inhibitor decreased their MMC tolerance. In the nonresistant cells, overexpression and silencing of AKR1B10 decreased and increased, respectively, susceptibility to cytotoxic effects of MMC and 4-hydroxy-2-nonenal, which was formed as a product of lipid peroxidation by MMC treatment. These results suggest a role of AKR1B10 in the development of MMC resistance, which may be mediated by its ability to detoxify cytotoxic aldehydes including 4-hydroxy-2-nonenal. Anti-Cancer Drugs 22:402-408 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams Wilkins.
UR - http://www.ncbi.nlm.nih.gov/pubmed/21317765
U2 - 10.1097/CAD.0b013e3283448df0
DO - 10.1097/CAD.0b013e3283448df0
M3 - Article
SN - 0959-4973
VL - 22
SP - 402
EP - 408
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 5
ER -
